Congratulations to Nicolas ORTONNE’s MOON-LYT team, which has just been awarded the “FRM Team” designation, along with €443,700 in FRM funding!

At its meeting on March 12, 2026, the FRM Scientific Council/Ad Hoc Committee issued a favorable recommendation regarding the team’s funding application for its program on a new therapeutic strategy for T-cell lymphomas: “Preclinical studies for new combination therapies based on CD81 targeting or 5-azacitidine to treat peripheral T-cell lymphomas.”

This project, currently in the preclinical stage, has benefited in particular from the in vivo models (PDX mice with TFH lymphomas) developed by Professor François LEMONNIER in partnership with EP3.

This program is further supported by a patent application filed through Inserm Transfert, in which several team members are involved, notably Dr. Jérôme GIUSTINIANI, who initiated the study.

The FRM is awarding them a grant of €443,700 for a period of 36 months.